Objective:To observe the safety and efficacy of moxibustion at Shenque(CV 8)for chronic urticaria.Methods:A total of 80 cases who met the inclusion criteria were randomly allocated into a treatment group and a control...Objective:To observe the safety and efficacy of moxibustion at Shenque(CV 8)for chronic urticaria.Methods:A total of 80 cases who met the inclusion criteria were randomly allocated into a treatment group and a control group,40 in each.Cases in the treatment group were treated with thunder-fire moxibustion at Shenque(CV 8),whereas cases in the control group were treated with Mizolastine.Changes in clinical symptoms such as itching and skin lesion were observed before and after treatment and the therapeutic efficacies were assessed.Results:After treatment,the total scores of clinical symptoms in both groups were markedly reduced(P<0.05),and the reduction was more significant in the treatment group than that in the control group(P<0.05).The total effective rate in the treatment group was 77.5%,versus 65.0%in the control group,showing no significant difference(P>0.05).The Ridit analysis showed a between-group significant difference in therapeutic efficacy grades(P<0.05).There were no reports of adverse reactions in the treatment group and 2 cases experienced mild somnolence in the control group.Conclusion:With an exact effect for chronic urticaria,moxibustion at Shenque(CV 8)obtained better results in overall efficacy and improving symptoms than oral administration of Mizolastine.展开更多
OBJECTIVE: To systematically evaluate the clinical effects of herb-partitioned moxibustion on patients with primary dysmenorrhea. METHODS: Randomized controlled trials of herb-partitioned moxibustion for primary dysme...OBJECTIVE: To systematically evaluate the clinical effects of herb-partitioned moxibustion on patients with primary dysmenorrhea. METHODS: Randomized controlled trials of herb-partitioned moxibustion for primary dysmenorrhea published from the year the database was established to November, 2017 were searched from CNKI,Wanfang Database, VIP database, CBM, PubMed, Embase, and Cochrane Library. Data extraction and quality evaluation were performed in papers meeting inclusion criteria. The outcomes measurements included clinical effect rate, visual analogue score(VAS), plasma PGF2α, adverse events, recurrence rate, and quality of life. The Rev Man 5.3 software was applied for meta-analysis. RESULTS:(1) A total of 16 studies were eligible and included in the meta-analysis involved1126 patients.(2) A statistically significant increasing in clinical effective rate was found in HMP group compared with control group [OR=3.49, 95%CI(2.25, 5.39), P<0.00001].(3) There was significant difference between two groups in visual analogue score [MD=–7.48, 95%CI(–9.93, –5.02), P<0.00001], which suggested the patients who received HPM had lower VAS scales than those who received no HPM.(4) There was significantly difference in serum PGF2α between the groups receiving HPM and the control group [MD=–4.61, 95%CI(–9.19, –0.03), P=0.05].(5) 2 trials reported followup duration, and all included studies did not mention the recurrence of PD during the follow-up stage, and all included studies did not mention the improvement of quality of life of PD during period of management and follow-up stage.CONCLUSIONS: Herb-partitioned moxibustion is beneficial for primary dysmenorrhea. However, the conclusion is not completely accurate with limitations of the current RCTs. The safety of herb-partitioned moxibustion remains to be defined by future studies. Attention should be paid to long-term effects of herb-partitioned moxibustion in clinical research. High-quality RCTs are required to confirm the effectiveness of herb-partitioned moxibustion for primary dysmenorrhea.展开更多
基金supported by Jiading Hospital of Traditional Chinese Medicine
文摘Objective:To observe the safety and efficacy of moxibustion at Shenque(CV 8)for chronic urticaria.Methods:A total of 80 cases who met the inclusion criteria were randomly allocated into a treatment group and a control group,40 in each.Cases in the treatment group were treated with thunder-fire moxibustion at Shenque(CV 8),whereas cases in the control group were treated with Mizolastine.Changes in clinical symptoms such as itching and skin lesion were observed before and after treatment and the therapeutic efficacies were assessed.Results:After treatment,the total scores of clinical symptoms in both groups were markedly reduced(P<0.05),and the reduction was more significant in the treatment group than that in the control group(P<0.05).The total effective rate in the treatment group was 77.5%,versus 65.0%in the control group,showing no significant difference(P>0.05).The Ridit analysis showed a between-group significant difference in therapeutic efficacy grades(P<0.05).There were no reports of adverse reactions in the treatment group and 2 cases experienced mild somnolence in the control group.Conclusion:With an exact effect for chronic urticaria,moxibustion at Shenque(CV 8)obtained better results in overall efficacy and improving symptoms than oral administration of Mizolastine.
文摘OBJECTIVE: To systematically evaluate the clinical effects of herb-partitioned moxibustion on patients with primary dysmenorrhea. METHODS: Randomized controlled trials of herb-partitioned moxibustion for primary dysmenorrhea published from the year the database was established to November, 2017 were searched from CNKI,Wanfang Database, VIP database, CBM, PubMed, Embase, and Cochrane Library. Data extraction and quality evaluation were performed in papers meeting inclusion criteria. The outcomes measurements included clinical effect rate, visual analogue score(VAS), plasma PGF2α, adverse events, recurrence rate, and quality of life. The Rev Man 5.3 software was applied for meta-analysis. RESULTS:(1) A total of 16 studies were eligible and included in the meta-analysis involved1126 patients.(2) A statistically significant increasing in clinical effective rate was found in HMP group compared with control group [OR=3.49, 95%CI(2.25, 5.39), P<0.00001].(3) There was significant difference between two groups in visual analogue score [MD=–7.48, 95%CI(–9.93, –5.02), P<0.00001], which suggested the patients who received HPM had lower VAS scales than those who received no HPM.(4) There was significantly difference in serum PGF2α between the groups receiving HPM and the control group [MD=–4.61, 95%CI(–9.19, –0.03), P=0.05].(5) 2 trials reported followup duration, and all included studies did not mention the recurrence of PD during the follow-up stage, and all included studies did not mention the improvement of quality of life of PD during period of management and follow-up stage.CONCLUSIONS: Herb-partitioned moxibustion is beneficial for primary dysmenorrhea. However, the conclusion is not completely accurate with limitations of the current RCTs. The safety of herb-partitioned moxibustion remains to be defined by future studies. Attention should be paid to long-term effects of herb-partitioned moxibustion in clinical research. High-quality RCTs are required to confirm the effectiveness of herb-partitioned moxibustion for primary dysmenorrhea.
